Published in Mol Cancer Ther on September 01, 2005
Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res (2009) 2.00
Mechanisms of combined action of different chemopreventive dietary compounds: a review. Eur J Nutr (2008) 1.41
Natural products and colon cancer: current status and future prospects. Drug Dev Res (2008) 1.34
Mouse models for unraveling the importance of diet in colon cancer prevention. J Nutr Biochem (2010) 1.06
Rice bran fermented with saccharomyces boulardii generates novel metabolite profiles with bioactivity. J Agric Food Chem (2011) 1.02
Chemopreventive properties of dietary rice bran: current status and future prospects. Adv Nutr (2012) 1.00
CYP93G2 is a flavanone 2-hydroxylase required for C-glycosylflavone biosynthesis in rice. Plant Physiol (2010) 0.93
Consumption of rice bran increases mucosal immunoglobulin A concentrations and numbers of intestinal Lactobacillus spp. J Med Food (2012) 0.89
Brewers' rice induces apoptosis in azoxymethane-induced colon carcinogenesis in rats via suppression of cell proliferation and the Wnt signaling pathway. BMC Complement Altern Med (2014) 0.84
Rice varietal differences in bioactive bran components for inhibition of colorectal cancer cell growth. Food Chem (2013) 0.79
Non-apoptotic function of caspases in a cellular model of hydrogen peroxide-associated colitis. J Cell Mol Med (2013) 0.77
Scientific Evidence of Rice By-Products for Cancer Prevention: Chemopreventive Properties of Waste Products from Rice Milling on Carcinogenesis In Vitro and In Vivo. Biomed Res Int (2017) 0.77
Structure-function relationships of wheat flavone O-methyltransferase: Homology modeling and site-directed mutagenesis. BMC Plant Biol (2010) 0.75
Hypotheses on the Potential of Rice Bran Intake to Prevent Gastrointestinal Cancer through the Modulation of Oxidative Stress. Int J Mol Sci (2017) 0.75
Flavonoids: an overview. J Nutr Sci (2016) 0.75
Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res (2004) 3.51
Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev (2007) 2.45
Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev (2002) 2.26
Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res (2010) 1.89
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol (2005) 1.86
Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev (2005) 1.83
Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res (2010) 1.82
Resveratrol in human cancer chemoprevention--choosing the 'right' dose. Mol Nutr Food Res (2011) 1.77
Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev (2002) 1.69
Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol (2007) 1.68
Clinical trials of resveratrol. Ann N Y Acad Sci (2011) 1.66
Dietary polyphenolic phytochemicals--promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer (2007) 1.65
Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol (2006) 1.61
Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos (2004) 1.56
Do anthocyanins and anthocyanidins, cancer chemopreventive pigments in the diet, merit development as potential drugs? Cancer Chemother Pharmacol (2009) 1.51
Pilot study of oral anthocyanins for colorectal cancer chemoprevention. Cancer Prev Res (Phila) (2009) 1.50
Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev (2003) 1.49
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol (2007) 1.49
Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin Cancer Res (2004) 1.45
Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res (2006) 1.39
Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila) (2009) 1.31
Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.26
PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene (2004) 1.24
Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer (2008) 1.21
Anthocyans from fruits and vegetables--does bright colour signal cancer chemopreventive activity? Eur J Cancer (2005) 1.19
Innovative agents in cancer prevention. Recent Results Cancer Res (2005) 1.01
Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med (2013) 1.00
Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair (Amst) (2005) 0.99
Effect of cyanidin-3-glucoside and an anthocyanin mixture from bilberry on adenoma development in the ApcMin mouse model of intestinal carcinogenesis--relationship with tissue anthocyanin levels. Int J Cancer (2006) 0.98
Rapid analysis of curcumin and curcumin metabolites in rat biomatrices using a novel ultraperformance liquid chromatography (UPLC) method. J Agric Food Chem (2009) 0.98
Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability. Cancer Prev Res (Phila) (2012) 0.96
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res (2003) 0.95
Differential modulation of cyclooxygenase-mediated prostaglandin production by the putative cancer chemopreventive flavonoids tricin, apigenin and quercetin. Cancer Chemother Pharmacol (2006) 0.94
Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer (2008) 0.94
The role of imaging in the clinical development of antiangiogenic agents. Hematol Oncol Clin North Am (2004) 0.94
Breast cancer prevention by green tea catechins and black tea theaflavins in the C3(1) SV40 T,t antigen transgenic mouse model is accompanied by increased apoptosis and a decrease in oxidative DNA adducts. J Agric Food Chem (2007) 0.93
Determination of 8-oxo-2'-deoxyguanosine and creatinine in murine and human urine by liquid chromatography/tandem mass spectrometry: application to chemoprevention studies. Rapid Commun Mass Spectrom (2009) 0.92
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol (2003) 0.92
Resveratrol--a prostate cancer chemopreventive agent? Urol Oncol (2002) 0.91
Evaluation of the DNA damaging potential of cannabis cigarette smoke by the determination of acetaldehyde derived N2-ethyl-2'-deoxyguanosine adducts. Chem Res Toxicol (2009) 0.91
Liquid chromatographic assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.91
Putative cancer chemopreventive agents of dietary origin-how safe are they? Nutr Cancer (2007) 0.91
Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism. Prostate (2008) 0.90
Flavones as colorectal cancer chemopreventive agents--phenol-o-methylation enhances efficacy. Cancer Prev Res (Phila) (2009) 0.90
Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer. Am J Clin Oncol (2013) 0.90
Development of a targeted adductomic method for the determination of polycyclic aromatic hydrocarbon DNA adducts using online column-switching liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2010) 0.89
Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo. Int J Cancer (2010) 0.89
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer. J Pain Symptom Manage (2008) 0.88
Simultaneous determination of 8-oxo-2'-deoxyguanosine and 8-oxo-2'-deoxyadenosine in DNA using online column-switching liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2009) 0.88
Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels. Eur J Cancer (2008) 0.87
Curcumin in cancer management: recent results of analogue design and clinical studies and desirable future research. Mol Nutr Food Res (2008) 0.87
Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents. Eur J Med Chem (2012) 0.87
Pharmacokinetics and metabolism of the putative cancer chemopreventive agent cyanidin-3-glucoside in mice. Cancer Chemother Pharmacol (2009) 0.86
Hepatic gene expression in protoporphyic Fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool. Am J Pathol (2005) 0.86
Use of cancer chemopreventive phytochemicals as antineoplastic agents. Lancet Oncol (2005) 0.86
Tissue distribution in mice and metabolism in murine and human liver of apigenin and tricin, flavones with putative cancer chemopreventive properties. Cancer Chemother Pharmacol (2006) 0.85
Gene expression profiles associated with inflammation, fibrosis, and cholestasis in mouse liver after griseofulvin. EHP Toxicogenomics (2003) 0.85
Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer. Exp Toxicol Pathol (2005) 0.85
Histopathology of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists. Toxicol Pathol (2007) 0.85
Resveratrol in the management of human cancer: how strong is the clinical evidence? Ann N Y Acad Sci (2013) 0.85